Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Prebiotic blends are formulated with non-digestible fibers (such as inulin, fructooligosaccharides, and galactooligosaccharides) that selectively stimulate the growth and/or activity of beneficial gut bacteria. The scientific rationale for using prebiotics in colitis, particularly ulcerative colitis (UC) and Crohn’s disease, is anchored in the role of the gut microbiota in maintaining intestinal health and immune regulation. Several studies, including randomized controlled trials and animal models, have demonstrated that prebiotic supplementation can alter the gut microbiome by increasing populations of protective bacteria like Bifidobacteria and Lactobacilli. These changes are associated with increased production of short-chain fatty acids (SCFAs), particularly butyrate, which has anti-inflammatory properties and supports the integrity of the colonic mucosal barrier.

Clinical data, although limited and sometimes inconsistent, suggest potential benefits of prebiotic supplementation in improving symptoms, reducing inflammatory markers, and promoting mucosal healing in patients with inflammatory bowel disease (IBD), including colitis. For example, some trials have shown reduced disease activity or improved quality of life in UC patients taking prebiotics, though effects may be modest and not all studies are positive. Overall, while there is scientific evidence supporting the use of prebiotic blends as an adjunct in colitis management, it is not yet robust or universally accepted, warranting a moderate evidence rating of 3. Further large-scale, well-designed clinical trials are needed to confirm efficacy and optimal formulations.

More about prebiotic blend (proprietary)
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by prebiotic blend (proprietary)

Products containing prebiotic blend (proprietary)